CD19 immunostaining of a stored paraffin-embedded vitrectomy cell block of intraocular lymphoma contributing to chimera antigen receptor T-cell therapy.

IF 0.9 Q4 HEMATOLOGY

Journal of Clinical and Experimental Hematopathology Pub Date : 2022-09-28 Epub Date: 2022-06-22 DOI:10.3960/jslrt.22007

Toshihiko Matsuo, Takehiro Tanaka, Nobuharu Fujii, Kentaro Fujii, Eisei Kondo

{"title":"CD19 immunostaining of a stored paraffin-embedded vitrectomy cell block of intraocular lymphoma contributing to chimera antigen receptor T-cell therapy.","authors":"Toshihiko Matsuo, Takehiro Tanaka, Nobuharu Fujii, Kentaro Fujii, Eisei Kondo","doi":"10.3960/jslrt.22007","DOIUrl":null,"url":null,"abstract":"autologous peripheral blood hematopoietic stem cell transplantation in preconditioning with busulfan and thiotepa. 5 She maintained complete remission for 3 years until the age of 50 years when head magnetic resonance imaging showed high-signal lesions on the T2-weighted FLAIR image again in the right occipital lobe. She had 5 courses of methotrexate CHOP chemotherapy combined with rituximab for half a year, leading to complete remission, and then underwent chimera antigen receptor T-cell therapy (tisagenlecleucel) based on the CD19 expression of lymphoma cells in the preserved vitrectomy cell block (Fig. 1C). One year later, she devel-oped impending branch retinal vein occlusion with retinal blot hemorrhages, venous dilation and tortuosity in the right eye, and showed spontaneous resolution in the 4 months. Otherwise, she had shown neither retinal manifestations nor recurrent vitreous opacity throughout the course. She was systemically well for 1.5 years and maintained the best-cor-rected visual acuity of 1.5 in both eyes until the latest follow-up at the age of 52 years.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/72/f2/jslrt-62-187.PMC9635033.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical and Experimental Hematopathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3960/jslrt.22007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/6/22 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

autologous peripheral blood hematopoietic stem cell transplantation in preconditioning with busulfan and thiotepa. 5 She maintained complete remission for 3 years until the age of 50 years when head magnetic resonance imaging showed high-signal lesions on the T2-weighted FLAIR image again in the right occipital lobe. She had 5 courses of methotrexate CHOP chemotherapy combined with rituximab for half a year, leading to complete remission, and then underwent chimera antigen receptor T-cell therapy (tisagenlecleucel) based on the CD19 expression of lymphoma cells in the preserved vitrectomy cell block (Fig. 1C). One year later, she devel-oped impending branch retinal vein occlusion with retinal blot hemorrhages, venous dilation and tortuosity in the right eye, and showed spontaneous resolution in the 4 months. Otherwise, she had shown neither retinal manifestations nor recurrent vitreous opacity throughout the course. She was systemically well for 1.5 years and maintained the best-cor-rected visual acuity of 1.5 in both eyes until the latest follow-up at the age of 52 years.

Abstract Image